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We report the first case of Segniliparus rotundus pneumonia in an adult with non-cystic fibrosis bronchiec-
tasis. All isolates were identified as S. rotundus by 16S rRNA gene sequencing and rpoB PCR-restriction
analysis. Antibiotic therapy with clarithromycin and ciprofloxacin for 2 months improved the patient’s con-
dition and achieved successful sputum conversion.
CASE REPORT
A 43-year-old woman was referred to Samsung Medical
Center for chronic cough and sputum lasting more than 3
months. The patient’s medical history included a tuberculous
pleurisy at the age of 22 years. She lived in an urban area and
had no history of smoking, alcoholism, or immunosuppressive
drug use.
A human immunodeficiency virus (HIV) antibody test was
negative. A high-resolution computed tomography (HRCT)
chest scan revealed severe bronchiectasis, multiple small nod-
ules, and branching centrilobular nodules. These findings sug-
gested bronchiolitis, especially in the right lung (Fig. 1). There
was no evidence indicating a specific cause of the bronchiec-
tasis, such as cystic fibrosis. Multiple sputum specimens were
examined for mycobacteria. The specimens were decontami-
nated and concentrated with NaOH plus N-acetyl-L-cysteine.
Acid-fast bacilli (AFB) were detected more than five times on
both auramine-rhodamine fluorescent stain and Ziehl-Neelsen
methods, and liquid cultures of these multiple sputum speci-
mens were incubated for 9 to 11 days with a Bactec MGIT 960
system (BD Diagnostics, Sparks, MD).
To diagnose the etiological agent, bacteria grown in the
MGIT 960 culture system were initially propagated in 7H9
broth (Difco Laboratories, Detroit, MI) supplemented with
10% (vol/vol) oleic acid-albumin-dextrose-catalase (OADC;
Becton Dickinson) for 7 days at 37°C and genomic DNA was
extracted from cultured bacteria. Initial species identification
using a reverse line blot hybridization assay (REBA Myco-ID;
M&D, Inc., Wonju, South Korea) was unsuccessful. Because
this assay was designed to detect and identify Mycobacterium
tuberculosis and 19 species of nontuberculous mycobacteria
(NTM) (7), we considered our samples to be outside this
detection range. We conducted a PCR-restriction fragment
length polymorphism analysis (PRA) of the hsp65 and rpoB
genes (Table 1) which has been used effectively for the simul-
taneous identification of many mycobacterial species (4, 8, 11).
Digestion of the hsp65 gene at 37°C with MspI (New England
BioLabs, MA) produced a 527-bp segment of the amplified
PCR product, displaying a restriction pattern of 250-, 105-, and
75-bp DNA fragments (Fig. 2). This restriction pattern was
identical to previously reported patterns of Segniliparus rotun-
dus and S. rugosus (1). To confirm these results, reference
strains of S. rotundus CIP 108380T and S. rugosus CIP 108378T
(Institut Pasteur, Paris, France) were included in subsequent
experiments. PRA of the hsp65 gene found no difference be-
tween a clinical isolate and the two reference strains. PRA of
the rpoB gene was performed using MspI and HaeIII to further
distinguish the two species. These restriction enzymes were
selected from the rpoB genes of S. rotundus CIP 108380T (10)
and S. rugosus (GenBank accession no. GL622756). The rpoB
PRA using MspI and HaeIII restriction showed a unique di-
gestion pattern for S. rotundus that distinguished it from S.
rugosus and Mycobacterium spp. (Fig. 2) (11). Furthermore, the
rpoB PRA of the clinical isolate using these two enzymes dis-
played a pattern identical to that of S. rotundus CIP 108380T.
To confirm the accuracy of this identification, sequencing
analyses of rpoB (7), the 16S–23S rRNA internal transcribed
spacer (ITS) sequence (5), and 16S rRNA were performed (9).
The rpoB sequences showed 99% similarity, and the 16S–23S
rRNA ITS and 16S rRNA sequences showed 100% similarity
to that of the S. rotundus reference strain (GenBank accession
no. CP001958 and FJ468343) (10).
Drug susceptibility testing was performed at the Korean
Institute of Tuberculosis by using a broth microdilution
method in the same manner as used for rapidly growing
mycobacteria (RGM), according to the guidelines of the
Clinical and Laboratory Standards Institute (CLSI) (3, 12).
MICs were determined after incubation at 30°C for 3 days.
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The Segniliparus species reference strains and the clinical
isolate were resistant to amikacin, sulfamethoxazole, tobra-
mycin, and ethambutol. The clinical isolate was more resis-
tant than S. rotundus CIP 108380T to cefoxitin, doxycycline,
and imipenem. The clinical isolate and S. rotundus CIP
108380T were susceptible to clarithromycin, ciprofloxacin,
and moxifloxacin (Table 2).
The patient was treated with oral clarithromycin (1,000 mg/
day) and ciprofloxacin (1,000 mg/day) for 2 months. The treat-
ment outcome was favorable; the patient’s symptoms resolved
completely, radiographic findings improved, and sputum smear
and culture were negative after 2 months of antibiotic therapy.
Segniliparus is a novel genus consisting of two species (S.
rotundus and S. rugosus) that was first named in 2005 (1). Both
reference strains of Segniliparus were isolated from human
sputum (1, 10), and the characterization study demonstrated
that they shared some phenotypical characteristics with rapidly
growing mycobacteria (1).
In this article, we have described a case of S. rotundus pneu-
monia in a patient with non-cystic fibrosis bronchiectasis. To
our knowledge, this is the first reported case of S. rotundus
pneumonia. S. rugosus in patients with cystic fibrosis in the
United States and Australia has recently been reported (2, 6).
These cases suggest that Segniliparus species may be emerging
respiratory pathogens that can cause pneumonia in patients
with bronchiectasis.
The accurate identification of bacteria is important for the
evaluation of the clinical implications of emerging pathogens
in respiratory infections. However, Segniliparaceae may be con-
fused with nonchromogenic rapidly growing mycobacteria in
microscopic examination, due to the acid-fast staining proper-
ties of these species. In our case, molecular diagnostic methods
allowed the accurate identification of S. rotundus and its dif-
ferentiation from mycobacteria and S. rugosus, especially in the
sequencing analyses of 16S rRNA genes and rpoB PRA using
MspI and HaeIII.
Few studies of S. rotundus infection have been published,
and reliable information about antibiotic therapy is limited.
The S. rotundus reference strain and isolate were susceptible to
several oral antibiotics, including clarithromycin, ciprofloxacin,
and moxifloxacin. In contrast, the S. rugosus reference strain
was highly resistant to these antibiotics. These results were
consistent with those of previous studies (2, 6). Our patient
FIG. 1. A 43-year-old woman with Segniliparus rotundus pneumo-
nia. (A) A high-resolution computed tomography (HRCT) chest scan
at the level of the proximal lower lobar bronchus shows extensive
bronchiectasis and lobular consolidation. (B) An HRCT scan obtained
at the lung base shows severe bronchiectasis in the right middle lobe.
Multiple small nodules and branching centrilobular nodules form a
tree-in-bud pattern in the right lower lobe.
TABLE 1. Genes and oligonucleotide primers used and percent similarity in sequencing analysis with Segniliparus rotundus
reference strain (GenBank accession no. CP001958)
Gene Primer sequence (5–3)c Product size (bp) Similarity (%) Reference
hsp65 (F) GAG GGC GTC ATC ACC GTC GAG G 527 NAd 4
(R) CGG CGA TGG CGT CGG AGT CAC C
rpoBa (F) TCA AGG AGA AGC GCT ACG A 360 99 7
(R) GGA TGT TGA TCA GGG TCT GC
16S-23S ITSb (F) TTGTACACACCGCCCGTCA 487 100 10
(R) TCTCGATGCCAAGGCATCCACC
16S rRNA (F) GAGTTTGATCCTGGCTCAGGA 560 100 9
(R) AAGGAGGTGATCCAGCCGCA
a The gene used in both molecular methods of PRA and sequence analysis.
b 16S-23S rRNA internal transcribed spacer of mycobacteria.
c F, forward; R, reverse.
d NA, not applicable, due to no information.
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showed symptomatic, radiographic, and microbiological im-
provements after 2 months of treatment with clarithromycin
and ciprofloxacin. Further studies should seek to establish the
optimal antibiotic therapy for S. rotundus infection.
Clinicians and physicians should be aware that AFB bacteria
other than Mycobacterium spp. in respiratory infections may be
S. rotundus, and further studies should investigate the signifi-
cance and clinical importance of Segniliparus species.
This work was supported by National Research Foundation of Ko-
rea (NRF) grant no. 2011-0006228 funded by the Korean government
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FIG. 2. PCR restriction-enzyme polymorphism analysis (PRA). (A) Simulation of PRA of the hsp65 and rpoB genes. (B) PRA electrophoresis
results. M, size marker; lanes 1 to 3, hsp65 amplicons digested by MspI from S. rugosus CIP 108378T, S. rotundus CIP 108380T, and the clinical
isolate of this case, respectively; lines 4 to 6, rpoB amplicons digested by MspI from S. rugosus CIP 108378T, S. rotundus CIP 108380T, and the
clinical isolate of this case, respectively; lines 7 to 9, rpoB amplicons digested by HaeIII from S. rugosus CIP 108378T, S. rotundus CIP 108380T,
and the clinical isolate of this case, respectively.
TABLE 2. Antimicrobial susceptibility patterns for S. rotundus and











Amikacin 128 128 128
Cefoxitin 256 2 8
Ciprofloxacin 1 0.125 16
Clarithromycin 2 4 64
Doxycycline 32 2 32
Imipenem 16 0.5 4
Moxifloxacin 1 0.125 0.125
Rifampin 16 0.125 16
Sulfamethoxazole 128 16 128
Tobramycin 32 32 32
Ethambutol 32 32 32
a MICs were interpreted using criteria for mycobacteria and aerobic actino-
mycetes.
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